Studies on the metabolic fate of M17055, a novel diuretic (6). Assessment for drug-drug interactions of M17055 in metabolism, distribution and excretion

References

• ABE, T., UNNO, M., ONOGAWA, T. and ToKul, T., 2001, Molecular identification of organic anion transporter oatp/LST family. Tanpakushitsu Kakusan Koso, 46, 612–620.
   PubMedGoogle Scholar
• ANDREASEN, F., HANSEN, U., HUSTED, S. E. and JANSEN, J. A., 1983, The pharmacokinetics of frusemide are influenced by age. British journal of Clinical Pharmacology, 16, 391–397.
   PubMed Web of Science ®Google Scholar
• ANDREASEN, F., SIGURD, B. and STEINESS, E., 1980, Effect of probenecid on excretion and natriuretic action of furosemide. European Journal of Clinical Pharmacology, 18, 489–495.
   PubMed Web of Science ®Google Scholar
• ARITA, T., HORI, R., OWADA, E. and TAKAHASHI, K., 1969, Transformation and excretion of drugs in biological systems. I. Renal excretion mechanisms of sulfonamides (1). Chemical and Pharmaceutical Bulletin, 17, 2526–2532.
   PubMed Web of Science ®Google Scholar
• BIDIVILLE, J. and ROCH-RAMEL, F., 1986, Competition of organic anions for furosemide and p-aminohippurate secretion in the rabbit. Journal of Pharmacology and Experimental Therapeutics, 237, 636–643.
   Google Scholar
• BONATE, P. L., REITH, K. and WEIR, S., 1998, Drug interactions at the renal level. Clinical Pharmacokinetics, 34, 375–404.
   PubMed Web of Science ®Google Scholar
• BOURRIE, M., MEUNIER, V., BERGER, Y. and FABRE, G., 1996, Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 277, 321–332.
   PubMed Web of Science ®Google Scholar
• BRATER, D. C., LEINFELDER, J. and ANDERSON, S. A., 1987, Clinical pharmacology of torasemide, a new loop diuretic. Clinical Pharmacology and Therapeutics, 42, 187–192.
   PubMed Web of Science ®Google Scholar
• DIXEY, J. J., NOORMOHAMED, F. H., PAWA, J. S., LANT, A. F. and BREWERTON, D. A., 1988, The influence of nonsteroidal anti-inflammatory drugs and probenecid on the renal response to and kinetics of piretanide in man. Clinical Pharmacology and Therapeutics, 44, 531–539.
   PubMed Web of Science ®Google Scholar
• ELLIOTT, H. L., ANSARI, A. F., CAMPBELL, B. C. and LAWRENCE, J. R., 1982, Protein binding of piretanide in normal and uraemic serum. European Journal of Clinical Pharmacology, 21, 311–313.
   PubMed Web of Science ®Google Scholar
• FEHSKE, K. J., MULLER, W. E. and WOLLERT, U., 1981, The location of drug binding sites in human serum albumin. Biochemical Pharmacology, 30, 687–692.
   PubMed Web of Science ®Google Scholar
• KNAUF, H. and MUTSCHLER, E., 1998, Clinical Pharmacokinetics and pharmacodynamics of torasemide. Clinical Pharmacokinetics, 34, 1–24.
   PubMed Web of Science ®Google Scholar
• KO, J.-W., SUKHOYA, N., THACKER, D., CHEN, P. and FLOCKHART, D. A., 1997, Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metabolism and Disposition, 25, 853–862.
   PubMed Web of Science ®Google Scholar
• NAKAJIMA, H., NAHA, H., NAKANISHI, T., NAKAI, K., WATANABE, T., IDA, K. and OHZAWA, N., 2002b, Studies on the metabolic fate of M17055, a novel diuretic (5): pharmacokinetics and pharmacodynamics of unchanged drug in rat and dog after intravenous administration of M17055. Drug Metabolism and Pharmacokinetics, 17, 214–220.
   PubMedGoogle Scholar
• NAKAJIMA, H., NAKANISHI, T., NABA, H., IDA, K. and OHZAWA, N., 2001b, Studies on the metabolic fate of M17055, a novel diuretic (2): tissue distribution and transfer of radioactivity into fetus and milk in rat after a single intravenous administration of [14C]M17055. Xenobiotic Metabolism and Disposition, 16, 314–324.
   Google Scholar
• NAKAJIMA, H., NAKANISHI, T., NABA, H., IDA, K. and OHZAWA, N., 2001c, Studies on the metabolic fate of M17055, a novel diuretic (3): plasma concentration, distribution and excretion of radioactivity in male rats after repeated daily intravenous administration of [14C]M17055. Xenobiotic Metabolism and Disposition, 16, 325–332.
   Google Scholar
• NAKAJIMA, H., NAKANISHI, T., NABA, H., TANAKA, H., IDA, K., OGIHARA, T. and OHZAWA, N., 2001a, Studies on the metabolic fate of M17055, a novel diuretic (1): plasma concentration and excretion of radioactivity in rat and dog after a single intravenous administration of [14C]M17055. Xenobiotic Metabolism and Disposition, 16, 304–313.
   Google Scholar
• NAKAJIMA, H., NAKANISHI, T., NAKAI, K., MATSUMOTO, S., IDA, K., OGIHARA, T. and OHZAWA, N., 2002a, Studies on the metabolic fate of M17055, a novel diuretic (4): species difference in metabolic pathway and identification of human CYP isoform responsible for the metabolism of M17055. Drug Metabolism and Pharmacokinetics, 17, 60–74.
   PubMedGoogle Scholar
• NEWTON, D. J., WANG, R. W. and Lu, A. Y. H., 1995, Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154–158.
   PubMed Web of Science ®Google Scholar
• ONO, S., HATANAKA, T., HOTTA, H., SATOH, T., GONZALEZ, F. J. and TSUTSUI, M., 1996, Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica, 26, 681–693.
   PubMed Web of Science ®Google Scholar
• SHINKAWA, T., NAKAJIMA. H., NISHIJIMA, K., YAMASAKI, F., KATO, K., OHZAWA, N. and MIZOTA, M., 1992a, A novel quinolinone diuretic, M12285, and its activation mechanism through sulfate conjugation. European journal of Pharmacology, 219, 217–224.
   Google Scholar
• SHINKAWA, T., YAMASAKI, F., KIKUCHI, A., NAKAKUKI, M., NISHIJIMA, K., UEMURA, A., MIZOTA, M. and ORITA, Y., 19926, Pharmacological properties of the novel highly potent diuretic 7-chloro-2,3-dihydro-1-(2-methylbenzoy1)-4(1H)-quinolinone 4-oxime-0-sulfonic acid potassium salt. Arzneimittel-ForschunglDrug Research, 42, 1466–1472.
   Google Scholar
• SHINKAWA, T., YAMASAKI, F., NOTSU, T., NAKAKUKI, M., NISHIJIMA, K., YOSHITOMI, K., and Imm, M., 1993, Loop and distal actions of a novel diuretic, M17055. European Journal of Pharmacology, 238, 317–325.
   PubMed Web of Science ®Google Scholar
• TANAKA, Y., DEGUCHI. Y., Ismi, I. and TERAI, T., 1991, Sex differences in excretion of zenarestat in rat. Xenobiotica, 21, 1119–1125.
   Google Scholar
• TERASHITA, S., SAWAMOTO, T., DEGUCHI, S., TOKUMA, Y. and HATA, T., 1995, Sex-dependent and independent renal excretion of nilvadipine metabolites in rat: evidence for a sex-dependent active secretion in kidney. Xenobiotica, 25, 37–47.
   PubMed Web of Science ®Google Scholar
• THE EUROPEAN AGENCY FOR THE EVALUATION OF MEDICAL PRODUCTS, COMMITTEE FOR PROPRIETARY MEDICAL PRODUCTS, 1997, Note for Guidance on the Investigation of Drug Interactions, pp. 3–7.
   Google Scholar
• UWAI, Y., SAITO, H., HASHIMOTO, Y. and INui, K., 2000b, Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. Journal of Pharmacology and Experimental Therapeutics, 295, 261–265.
   PubMed Web of Science ®Google Scholar
• UWAI, Y., SAITO, H. and INui, K., 2000a, Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter. European Journal of Pharmacology, 409, 31–36.
   PubMed Web of Science ®Google Scholar
• WEINER, I. M., WASHINGTON, J. A. and MUDGE, G. H., 1959, Studies On the renal excretion of salicylate in the dog. Bulletin of the Johns Hopkins Hospital, 105, 284–297.
   PubMedGoogle Scholar
• ZEEUW, D., JACOBSON, H. R. and BRATER, D. C., 1988, Indomethacin secretion in the isolated perfused proximal straight rabbit tubule. Journal of Clinical Investigation, 81, 1585–1592.
   PubMed Web of Science ®Google Scholar